Nowain Arash, Bhakta Hetal, Pais Shireen, Kanel Gary, Verma Sumita
Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA 90033, USA.
J Gastroenterol Hepatol. 2005 Jun;20(6):818-24. doi: 10.1111/j.1440-1746.2005.03720.x.
Abstract Gastrointestinal stromal tumors (GIST), although the most common mesenchymal neoplasms of the gastrointestinal (GI) tract, account for <1% of all GI malignancies. Up to 94% of these tumors express the CD117 antigen. Most patients present in the fifth to seventh decade, the commonest symptom being that of an abdominal mass. Surgery is the main modality of therapy, but even after adequate resection the vast majority of GIST reoccur, and in approximately 50% the liver is the main site of the metastasis. Long-term, maybe even lifelong follow up of these patients after initial resection cannot be over-emphasized. Initial tumor size and mitotic rate are the most useful parameters to predict malignant potential. In view of high postoperative recurrence, adjuvant forms of therapy are being explored, and the tyrosine kinase inhibitor imatinib holds the most promise.
摘要 胃肠道间质瘤（GIST）虽是胃肠道最常见的间叶性肿瘤，但在所有胃肠道恶性肿瘤中所占比例不到1%。这些肿瘤中高达94%表达CD117抗原。大多数患者发病于50至70岁，最常见的症状是腹部肿块。手术是主要的治疗方式，但即使进行了充分切除，绝大多数GIST仍会复发，约50%的患者肝脏是主要转移部位。对这些患者在初次切除后进行长期甚至终身随访再怎么强调都不为过。初始肿瘤大小和有丝分裂率是预测恶性潜能最有用的参数。鉴于术后高复发率，正在探索辅助治疗形式，酪氨酸激酶抑制剂伊马替尼最具前景。
